期刊
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
卷 130, 期 3, 页码 607-+出版社
MOSBY-ELSEVIER
DOI: 10.1016/j.jaci.2012.02.019
关键词
Hypereosinophilic syndrome; eosinophilic leukemia; criteria; classification; hypereosinophilia of undetermined significance
资金
- Medical University of Vienna
- Novartis
- Bristol-Myers Squibb
- National Institutes of Health
- Mayo Foundation
- GlaxoSmithKline
- University of Utah
- Ception
- Cephalon
- Teva
- Immune Design
Eosinophilia is an important indicator of various neoplastic and nonneoplastic conditions. Depending on the underlying disease and mechanisms, eosinophil infiltration can lead to organ dysfunction, clinical symptoms, or both. During the past 2 decades, several different classifications of eosinophilic disorders and related syndromes have been proposed in various fields of medicine. Although criteria and definitions are, in part, overlapping, no global consensus has been presented to date. The Year 2011 Working Conference on Eosinophil Disorders and Syndromes was organized to update and refine the criteria and definitions for eosinophilic disorders and to merge prior classifications in a contemporary multidisciplinary schema. A panel of experts from the fields of immunology, allergy, hematology, and pathology contributed to this project. The expert group agreed on unifying terminologies and criteria and a classification that delineates various forms of hypereosinophilia, including primary and secondary variants based on specific hematologic and immunologic conditions, and various forms of the hypereosinophilic syndrome. For patients in whom no underlying disease or hypereosinophilic syndrome is found, the term hypereosinophilia of undetermined significance is introduced. The proposed novel criteria, definitions, and terminologies should assist in daily practice, as well as in the preparation and conduct of clinical trials. (J Allergy Clin Immunol 2012;130:607-12.)
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据